Related Experiment Video
Updated: Aug 15, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
Published on: December 2, 2016
The pregnancy hormone relaxin is a player in human heart failure
T Dschietzig1, C Richter, C Bartsch
1Medizinische Klinik und Poliklinik (Kardiologie, Angiologie, Pulmologie) Charité, Campus Mitte, 10098 Berlin, Germany.
Abstract:
Human congestive heart failure is characterized by complex neurohumoral activation associated with the up-regulation of vasoconstricting and salt-retaining mediators and the compensatory rise of counter-regulatory hormones. In the present study, we provide the first evidence that relaxin (RLX), known as a pregnancy hormone, represents a potential compensatory mediator in human heart failure: plasma concentrations of RLX and myocardial expression of the two RLX genes (H1 and H2) correlate with the severity of disease and RLX responds to therapy. The failing human heart is a relevant source of circulating RLX peptides, and myocytes as well as interstitial cells produce RLX. Elevation of ventricular filling pressure up-regulates RLX expression and the hormone acts as a potent inhibitor of endothelin 1, the most powerful vasoconstrictor in heart failure. Furthermore, RLX modulates effects of angiotensin II, another crucial mediator. Our data identify RLX as a new player in human heart failure with potential diagnostic and therapeutic relevance.
Related Concept Videos
Hormonal Regulation
Pathophysiology of Heart Failure
Heart Failure Drugs: Diuretics
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Mitral Regurgitation I: Introduction
Heart Failure II: Pathophysiology

